Walleye Capital
CTKB icon

Walleye Capital’s Cytek Biosciences CTKB Stock Holding History

Walleye Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,474
Closed -$85.4K – 5033
2023
Q3 		$85.4K Buy
+15,474
New +$124K ﹤0.01% 4010
2023
Q2 		– Sell
-18,790
Closed -$173K – 4407
2023
Q1 		$173K Sell
18,790
-88,653
-83% -$954K ﹤0.01% 2576
2022
Q4 		$1.1M Buy
107,443
+92,899
+639% +$1.25M 0.02% 946
2022
Q3 		$214K Buy
+14,544
New +$189K ﹤0.01% 2061
2022
Q2 		– Sell
-97,852
Closed -$1.05M – 2425
2022
Q1 		$1.05M Buy
97,852
+32,032
+49% +$433K 0.03% 613
2021
Q4 		$1.07M Buy
65,820
+45,420
+223% +$951K 0.03% 548
2021
Q3 		$437 Buy
+20,400
New +$480K 0.01% 841

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Walleye Capital's CTKB Position: Q4 2023 in Review

Walleye Capital sold out of Cytek Biosciences (CTKB) in Q4 2023, closing a stake of 15,474 shares — an estimated $85.4K sold.

Walleye Capital first reported a position in CTKB in Q3 2021 and held it in 7 quarters. The position peaked at $1.1M in Q4 2022. 105 funds tracked by Wall St. Rank hold CTKB as of Q4 2023.

  • Walleye Capital reported no remaining Cytek Biosciences position as of Q4 2023 after selling out during the quarter.
  • Walleye Capital sold 15,474 Cytek Biosciences shares in Q4 2023, an estimated $85.4K.
  • Walleye Capital first reported a position in Cytek Biosciences in Q3 2021 and held it in 7 quarters.
  • Walleye Capital's Cytek Biosciences position peaked at $1.1M in Q4 2022.
  • 105 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.